Keyphrases
Adverse Events
33%
Albumin-bilirubin Grade
66%
Appetite Loss
33%
Atezolizumab Plus Bevacizumab
100%
BCLC Staging
33%
Bevacizumab Treatment
100%
Disease Control
33%
Drug Combination
33%
Early Clinical Exposure
100%
Early Response
33%
Early Tumor Shrinkage
33%
Function Response
33%
General Fatigue
33%
Hepatic Function
100%
Hepatocellular Carcinoma Patients
33%
Hypertension
33%
Imaging Examination
33%
Later-line Treatment
33%
Lenvatinib
33%
Molecular Targeted Agents
33%
Objective Response Rate
33%
Observation Period
66%
Post-progression
66%
Relative Change
33%
Response Evaluation Criteria in Solid Tumors (RECIST)
33%
Retrospective Clinical Study
33%
Shrinkage Control
33%
Systemic Treatment
66%
Therapeutic Potential
33%
Therapeutic Response
66%
Tumor Disease
33%
Unresectable Hepatocellular Carcinoma
100%
Urine Protein
33%
Medicine and Dentistry
Adverse Event
33%
Atezolizumab
100%
Bevacizumab
100%
Bilirubin
66%
Clinical Study
33%
Combination Drug
33%
Disease
33%
Hepatocellular Carcinoma
100%
Indium 111
33%
Lenvatinib
33%
Liver Function
100%
Loss of Appetite
33%
Neoplasm
33%
Response Evaluation Criteria in Solid Tumors
33%
Systemic Therapy
66%
Treatment Response
66%
Visual Evoked Potential
33%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
33%
Atezolizumab
100%
Bevacizumab
100%
Bilirubin
66%
Clinical Study
33%
Combination Drug
33%
Disease
33%
Indium 111
33%
Lenvatinib
33%
Liver Cell Carcinoma
100%
Loss of Appetite
33%
Molecular Target
33%
Neoplasm
33%
Solid Malignant Neoplasm
33%
Systemic Treatment
66%
Immunology and Microbiology
Atezolizumab
100%
Bevacizumab
100%
Lenvatinib
33%
Liver Function
100%
Protein Urine Level
33%
Visual Evoked Potential
33%